A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,083,972 shares of XENE stock, worth $83 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
2,083,972
Previous 1,839,555 13.29%
Holding current value
$83 Million
Previous $71.7 Million 14.33%
% of portfolio
0.15%
Previous 0.14%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.12 - $43.96 $8.83 Million - $10.7 Million
244,417 Added 13.29%
2,083,972 $82 Million
Q2 2024

Aug 14, 2024

BUY
$36.25 - $43.75 $6.08 Million - $7.33 Million
167,638 Added 10.03%
1,839,555 $71.7 Million
Q1 2024

May 15, 2024

BUY
$42.66 - $50.04 $26.6 Million - $31.2 Million
623,192 Added 59.42%
1,671,917 $72 Million
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $14.3 Million - $23.2 Million
498,725 Added 90.68%
1,048,725 $48.3 Million
Q3 2023

Nov 14, 2023

SELL
$34.16 - $39.73 $4.1 Million - $4.77 Million
-120,000 Reduced 17.91%
550,000 $18.8 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $2.79 Million - $3.48 Million
-80,000 Reduced 10.67%
670,000 $25.8 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $836,500 - $1.01 Million
25,000 Added 3.45%
750,000 $26.8 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $1.65 Million - $1.97 Million
50,000 Added 7.41%
725,000 $28.6 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $1.39 Million - $1.79 Million
45,000 Added 7.14%
675,000 $24.4 Million
Q2 2022

Aug 15, 2022

SELL
$25.44 - $35.16 $508,800 - $703,199
-20,000 Reduced 3.08%
630,000 $19.2 Million
Q1 2022

May 16, 2022

SELL
$25.09 - $33.13 $376,350 - $496,950
-15,000 Reduced 2.26%
650,000 $19.9 Million
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $7.96 Million - $18.1 Million
-510,000 Reduced 43.4%
665,000 $20.8 Million
Q3 2021

Nov 15, 2021

SELL
$14.86 - $19.45 $5.2 Million - $6.81 Million
-350,000 Reduced 22.95%
1,175,000 $18 Million
Q2 2021

Aug 16, 2021

SELL
$16.81 - $20.0 $17.2 Million - $20.5 Million
-1,025,000 Reduced 40.2%
1,525,000 $28.4 Million
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $1.37 Million - $2.13 Million
100,000 Added 4.08%
2,550,000 $45.6 Million
Q3 2020

Nov 16, 2020

BUY
$10.82 - $13.35 $4.6 Million - $5.67 Million
425,000 Added 20.99%
2,450,000 $27.1 Million
Q1 2020

May 15, 2020

BUY
$8.08 - $17.57 $808,000 - $1.76 Million
100,000 Added 5.19%
2,025,000 $23 Million
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $5.07 Million - $9.16 Million
625,000 Added 48.08%
1,925,000 $25.2 Million
Q4 2018

Feb 14, 2019

BUY
$5.61 - $12.62 $561,000 - $1.26 Million
100,000 Added 8.33%
1,300,000 $8.2 Million
Q3 2018

Nov 14, 2018

BUY
$9.0 - $14.9 $3.6 Million - $5.96 Million
400,000 Added 50.0%
1,200,000 $15.8 Million
Q2 2018

Aug 14, 2018

BUY
$4.8 - $9.2 $3.84 Million - $7.36 Million
800,000 New
800,000 $7.36 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.48B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.